primary biliary and sclerosing cholangitis
Both cause a cholestatic pattern (raised ALP, GGT). PBC: middle-aged women, AMA+, small intrahepatic ducts; UDCA 13–15 mg/kg/day for life, assess response at 12 months, add a second-line agent if inadequate. PSC: often young men with IBD, beaded large ducts on MRCP (not ERCP); no proven therapy; annual MRI/MRCP ± CA 19-9 for cholangiocarcinoma, colonoscopy every 1–2 years if IBD, cholecystectomy for gallbladder polyps >8 mm.
| PBC | PSC | |
|---|---|---|
| who | women 40–60 | men 30–40; ~70% have IBD (usually UC) |
| ducts | small intrahepatic (biopsy) | large intra/extrahepatic (MRCP: strictures + dilatation) |
| antibody | AMA (≥95%); if negative → anti-sp100, anti-gp210 | none specific (p-ANCA nonspecific) |
| associations | Sjögren’s, thyroid, coeliac | IBD, cholangiocarcinoma, gallbladder and colorectal cancer |
| treatment | UDCA → second-line if inadequate response | no proven disease-modifying therapy |
primary biliary cholangitis
Diagnosis — 2 of 3: raised ALP · AMA ≥1:40 · compatible histology. Cholestasis + AMA is enough; AMA-negative with anti-sp100/gp210 also needs no biopsy. Biopsy if antibody-negative, or ALT >5× ULN (concomitant AIH). Transplant referral when MELD >14; HCC surveillance in cirrhosis.
UDCA 13–15 mg/kg/day, lifelong; improves transplant-free survival in responders.
Response at 12 months — inadequate response (e.g. ALP ≥1.67× ULN or raised bilirubin) → high risk of progression:
| second-line | notes |
|---|---|
| obeticholic acid | contraindicated in advanced cirrhosis (decompensation or portal hypertension: ascites, varices, persistent thrombocytopenia); monitor closely in any cirrhosis |
| fibrates (bezafibrate, fenofibrate) | off-label; avoid in decompensated disease |
| PPAR agonists (seladelpar, elafibranor) | newer second-line agents |
Symptoms and complications:
- pruritus: cholestyramine (separate from UDCA by 4 h) → rifampicin (monitor LFTs) → naltrexone → sertraline
- fatigue — common, poorly treatable
- bone: DEXA at diagnosis and every 2 years; calcium, vitamin D; thyroid function yearly
- fat-soluble vitamins if prolonged cholestasis
- cirrhosis → HCC surveillance and varices (cirrhosis)
primary sclerosing cholangitis
Diagnosis:
- MRI/MRCP — multifocal strictures alternating with normal or dilated segments. ERCP is not for diagnosis.
- IgG4 in everyone — IgG4-related sclerosing cholangitis is steroid-responsive.
- No biopsy with typical MRCP (unless AIH overlap suspected). Normal MRCP with persistent cholestasis → biopsy for small-duct PSC.
- Colonoscopy with biopsies at diagnosis even without symptoms; if no IBD, repeat every 5 years or with symptoms.
Treatment:
- No proven therapy. UDCA 13–23 mg/kg/day can be tried if ALP stays raised; continue only if ALP falls or symptoms improve at 12 months. Avoid high-dose UDCA (28–30 mg/kg) — more adverse outcomes.
- Bacterial cholangitis → antibiotics; ERCP if not responding or a relevant stricture is found. Antibiotic prophylaxis for ERCP.
- Relevant (dominant) stricture → ERCP with brushings for cytology and FISH; balloon dilation.
- Pruritus → bile acid sequestrant first.
- Liver transplant for decompensation, recurrent cholangitis or intractable pruritus.
Surveillance:
- Cholangiocarcinoma and gallbladder cancer: MRI/MRCP ± CA 19-9 every year (not under 18, not small-duct PSC). CA 19-9 alone doesn’t diagnose cholangiocarcinoma (false positives with cholangitis).
- Gallbladder polyp >8 mm → cholecystectomy; ≤8 mm → US every 6 months.
- PSC + IBD → colonoscopy every 1–2 years from diagnosis (high-definition with biopsies) — CRC risk is high and right-sided (ulcerative colitis).
- Varices screening if LSM >20 kPa or platelets ≤150.
- Cirrhosis → HCC surveillance (hepatocellular carcinoma); bone density at diagnosis then every 2–3 years. Small-duct PSC → MRCP every 3–5 years for large-duct disease. Colonoscopy surveillance starts at age 15 in paediatric PSC-IBD.
Prepared 2026-10-28. Not yet verified — check every number against the sources.